REGENERON PHARMACEUTICALS INC. - COMMON STOCK

NetDania - New 12 months Low: REGENERON PHARMACEUTICALS INC. - COMMON STOCK

07 أبريل 2025 09:45:03 بحسب NetDania Notify

NetDania - New 12 months Low: REGENERON PHARMACEUTICALS INC. - COMMON STOCK

04 أبريل 2025 09:46:04 بحسب NetDania Notify

NetDania - New 12 months Low: REGENERON PHARMACEUTICALS INC. - COMMON STOCK

03 أبريل 2025 16:08:52 بحسب NetDania Notify

NetDania - New 12 months Low: REGENERON PHARMACEUTICALS INC. - COMMON STOCK

02 أبريل 2025 09:45:07 بحسب NetDania Notify

NetDania - New 12 months Low: REGENERON PHARMACEUTICALS INC. - COMMON STOCK

01 أبريل 2025 14:45:14 بحسب NetDania Notify

NetDania - New 12 months Low: REGENERON PHARMACEUTICALS INC. - COMMON STOCK

31 مارس 2025 09:50:37 بحسب NetDania Notify

Dupixent® (dupilumab) Approved as the First-ever Biologic Medicine in Japan for Patients with Chronic Obstructive Pulmonary Disease (COPD)

28 مارس 2025 02:00:14 بحسب Nasdaq GlobeNewswire

NetDania - New 12 months Low: REGENERON PHARMACEUTICALS INC. - COMMON STOCK

26 مارس 2025 09:46:28 بحسب NetDania Notify

Regeneron to Report First Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on April 29, 2025

25 مارس 2025 16:05:00 بحسب Nasdaq GlobeNewswire

NetDania - New 12 months Low: REGENERON PHARMACEUTICALS INC. - COMMON STOCK

25 مارس 2025 14:10:05 بحسب NetDania Notify

Regeneron Science Talent Search 2025 Awards More Than $1.8 Million to High School Seniors for Innovative Scientific Research on Classifying Objects in Space, Treating a Rare Muscle Disease and Solving a Long-Standing Math Problem

11 مارس 2025 21:32:16 بحسب Nasdaq GlobeNewswire

Dupixent® (dupilumab) Late-Breaking Positive Pivotal Data in Bullous Pemphigoid Presented at AAD

08 مارس 2025 13:00:00 بحسب Nasdaq GlobeNewswire

Linvoseltamab Recommended for EU Approval by the CHMP to Treat Relapsed/Refractory Multiple Myeloma

28 فبراير 2025 07:00:02 بحسب Nasdaq GlobeNewswire

Odronextamab BLA Accepted for FDA Review for the Treatment of Relapsed/Refractory Follicular Lymphoma

26 فبراير 2025 07:00:19 بحسب Nasdaq GlobeNewswire

Latest DB-OTO Results Demonstrate Clinically Meaningful Hearing Improvements in Nearly All Children with Profound Genetic Hearing Loss in CHORD Trial

24 فبراير 2025 15:00:04 بحسب Nasdaq GlobeNewswire

Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for the Targeted Treatment of Bullous Pemphigoid (BP)

18 فبراير 2025 00:59:00 بحسب Nasdaq GlobeNewswire

Regeneron Announces Investor Conference Presentations

11 فبراير 2025 16:05:00 بحسب Nasdaq GlobeNewswire

Linvoseltamab BLA Accepted for FDA Review for the Treatment of Relapsed/Refractory Multiple Myeloma

11 فبراير 2025 07:00:39 بحسب Nasdaq GlobeNewswire

EYLEA HD® (aflibercept) Injection 8 mg Positive Phase 3 Results in Patients with Macular Edema following Retinal Vein Occlusion Presented at Angiogenesis Meeting

08 فبراير 2025 17:40:16 بحسب Nasdaq GlobeNewswire

Three-Year Results for EYLEA HD® (aflibercept) Injection 8 mg in Patients with Wet Age-related Macular Degeneration Demonstrate Continued Durable Vision Gains and Anatomic Improvements with Extended Dosing Intervals

08 فبراير 2025 15:55:00 بحسب Nasdaq GlobeNewswire